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Asthma and nonasthmaticeosinophilicbronchitis (NAEB) are respiratory disorders characterized by a predominance of Th2 cells
andeosinophilicinﬂammation.Suppressorsofcytokinesignaling(SOCS)proteinsplayanimportantroleinTh2-mediated allergic
responses through control of the balance between Th1 and Th2 cells, particularly, SOCS3 and SOCS5. The aim of this study was
to analyze SOCS expression in human peripheral blood eosinophilsfrom patients withasthma,NAEB and healthy controls.SOCS
expression in eosinophils from subjects was demonstrated by diﬀerent techniques. Results showed that expression of SOCS3 in
eosinophilsand CD4 T cells from patients washigher than in healthy subjects. In addition, we demonstrated thatprostaglandin E2
(PGE2) and Th2 cytokines are able to upregulate SOCS3production in eosinophilsand attenuate its degranulation.In conclusion,
eosinophilsareabletotranscribeandtranslateSOCS3proteinandcancontributetotheregulationoftheTh1/Th2balancethrough
SOCS3 production.
1.Introduction
Th2 respiratory disorders, such as asthma, allergic rhinitis,
and nonasthmatic eosinophilic bronchitis (NAEB), have
been major public health problems in the last two decades.
NAEB was originally described by Gibson et al. [1]a n d
has subsequently been recognized as an important cause of
chronic cough [2]. Asthma and NAEB are associated with a
similar T-helper type2cytokine-drivenairway inﬂammation
[3, 4]. However, airway hyperresponsiveness and variable
airﬂow obstruction, which are the hallmarks of asthma, are
not present in NAEB.
Inﬂammatory mediators and cytokines play essential
roles in the control of immune system; they not only
act as growth factors, but also regulate the diﬀerentiation,
maintenance, and activation of na¨ ıve eﬀectors and the
memory state of immune cells [5]. The Th1/Th2 balance
determines the nature of an immune response [6]; however,
the mechanism by which Th1 and Th2 cytokines cross-
regulate the immune response remains unclear.
In both physiologic and pathologic conditions, cytokine
function is strictly controlled. Cytokine signaling pathways
are negatively regulated by the so-called suppressor of
cytokinesignaling (SOCS)family of proteins. There are eight
members of the CIS-SOCS family [7]. Several reports have
indicated that SOCS proteins are necessary for regulation
of normal immune responses [8]. SOCS proteins not only
act as simple negative-feedback regulators, but they are also
involved in ﬁne-tuning the immune response and in the
crosstalk of complicated cytokine signal networks. Since
cytokines are constantly present in the microenvironment
of immune cells, signal regulation by SOCS-family proteins
may be important for the proper progress, remission, and
relapse of an immune response. Therefore, SOCS1, SOCS3,
and SOCS5 participate in CD4+ Th-cell diﬀerentiation
and in Th1/Th2-cell balance [9]. SOCS3 is predominantly2 Clinical and Developmental Immunology
e x p r e s s e di nT h 2c e l l sa n di n h i b i t sT h 1d i ﬀerentiation [10–
12]. Conversely, SOCS5 is predominantly expressed in Th1
cells and inhibits Th2 diﬀerentiation [8, 13]. The cyclo-
oxygenase product, prostaglandin E2 (PGE2), is produced
by several cells in human airways, including the epithe-
lium [14] and smooth muscle [15]; PGE2 is produced
duringinﬂammatory responses, and increased levelsofPGE2
mediate some of the cardinal features of inﬂammation. In
contrast, several studies suggest that in addition to its pro-
inﬂammatory actions, PGE2 may also exert strong anti-
inﬂammatory and bronchoprotective eﬀects in patients with
bronchial asthma [15–18]. Recently, it has been demon-
strated that prostaglandins are capable of inducing SOCS3
expression [19–21]; moreover, we have reported that PGE2
is present in lung from subjects with NAEB and asthma
[22], diseases that are characterized by high eosinophil
counts. Thus, PGE2 may represent an endogenous protective
mechanism in the airways as a modulator of immune
responses.
The SOCS implication in Th1/Th2 balance regulation
and allergic phenotypes suggests a range of new therapeutic
strategies that could reduce Th2-induced inﬂammation and
eosinophilia.Forthesereasons,wedeterminedifeosinophils,
the characteristic inﬂammatory cells of asthma and NAEB,
a r ea b l et oe x p r e s sm R N Aa n ds y n t h e s i z eS O C S 3p r o t e i n , .I n
addition, we tested the hypothesis that both Th2 cytokines
and PGE2 upregulate SOCS3 expression in eosinophils. This
study reports SOCS3 production by eosinophils, a process
which is regulated by cytokines and PGE2.
2.Materialsand Methods
2.1. Subjects. Eight subjects with NAEB, 6 subjects with
asthma, and 9 healthy control subjects were recruited from
the Fundaci´ on Jimenez D´ ıaz Allergy clinic outpatients and
staﬀ. The investigation has been conducted according to
the principles expressed in the Declaration of Helsinki.
The study was approved by the Ethical Committee from
Fundaci´ on Jimenez D´ ıaz, and informed consent of all partic-
ipating subjects was obtained. Blood samples were obtained
from adult donors. Total IgE levels were measured using
the immunoCAP immunoassay system (Phadia, Uppsala,
Sweden) and PGE2 levels by ELISA kit (Cayman Chemical
Company, Ann Arbor, MI, USA).
Subjects with asthma had a consistent history of the
disease and objective evidence of asthma (as deﬁned by the
American Thoracic Society)[23] for at least 6 months. These
patients either showed a greater than 12% improvement in
FEV1, 10 minutes after administration of 500μgo fi n h a l e d
terbutaline, or had methacholine airway hyperresponsive-
ness (PC20 methacholine <16mg/mL). Patients with asthma
had mild persistent disease [24] and were clinically stable.
None had a history of respiratory infection for at least the
6-week period preceding the study. We included both atopic
and nonatopic patients in the asthmatic group, since no
diﬀerencesintheparametersassessed forbothsetsofpatients
had been observed previously.
The subjects with NAEB had an isolated cough last-
ing >8 weeks, no symptoms suggesting variable airﬂow
obstruction,normalspirometricvalues,amethacholinePC20
value >16mg/mL, a normal chest radiograph, and sputum
eosinophilia (sputum eosinophils >3%).
For patients who were receiving inhaled corticosteroids,
the drugs were withdrawn for at least 2 weeks before sputum
induction. No patient was receiving oral corticosteroids (for
at least 6 months prior to the study), leukotriene receptor
antagonists, aspirin, or any other cyclooxygenase inhibitor.
2.2. Eosinophil and CD4 T Cell Puriﬁcation. Eosinophils
and CD4 T cells were puriﬁed from peripheral blood
of healthy control and patient donors using a two-step
procedure. First, the polymorphonuclear and mononuclear
cell fractions were obtained byFicollgradient centrifugation.
The second step involved removal of residual cells from the
polymorphonuclear cell fraction. For eosinophil puriﬁca-
tion, CD2, CD3, CD14, CD16, CD19, CD20, CD36, CD56,
CD123, and glycophorin A positive cells were discarded by
a magnetic bead separation technique, as described in the
manufacturer’s procedure (EasySep; StemCell Technologies,
Vancouver, Canada). The CD4 T cell puriﬁcation from the
mononuclear fraction was achieved using a similar protocol
by removing monocytes, CD8 T cells, B cells and others
by a magnetic bead separation technique, using CD14,
CD16, CD19, CD20, CD36, CD56, CD123, TCRγ/δ,a n d
glycophorin A antibodies. Remaining cells were CD4 T
cells. The viability and purity of the cells were assessed by
staining with trypan blue and ﬂow cytometry, respectively.
Eosinophils are deﬁned as CCR3+CD16−cells, so we mea-
sured purity of eosinophils staining cells with ﬂuorochrome-
conjugated anti-CCR3 (CCR3-FITC) and anti-CD16 (CD16
PE) antibodies by ﬂow cytometry. The viability and purity
were routinely >98%.
2.3. Bronchial Biopsies. Bronchoscopies were performed
(healthy controls n = 2, asthma n = 2, and NAEB n = 4)
using a ﬂexible ﬁberoptic or rigid bronchoscope. Biopsies
were taken from the subcarinae of the left or right lower
lobe using fenestrated forceps and ﬁnally immersed in Trizol
reagent and frozen at −80◦Cu n t i lu s e .
2.4. Eosinophil Culture. Puriﬁed eosinophils from healthy
control, asthmatics, and NAEB subjects were plated at
1 × 106 cells/mL in RPMI 1640 with 10% fetal bovine
serum, 100U/mL penicillin, and 100μg/mL streptomycin at
37◦Ca n d5 %C O 2. Cells were then treated with diﬀerent
doses of recombinant human IL-4 or IL-5 (0.1, 1, and
10ng/mL; Bender MedSystem, Vienna, Austria) or IL-13
(0.5, 10 and 50ng/mL; R&D System, MN, USA) or PGE2
(10−4 and 10−6 M; Cayman Chemical Company, Ann Arbor
MI, USA) or IFNγ (5, 10, 20ng/mL; R&D System, MN,
USA)fordiﬀerenttime periods(30–120min). Allconditions
were performed in triplicate, in at least 4 independent
experiments.
2.5. Confocal Microscopy. Puriﬁed eosinophils (5 × 105 cells/
mL; 100μL/slide) were adhered to slides by cytocentrifuga-
tion (Shandon Southern Instruments, Waltham, MA, USA).
Adhered eosinophils were ﬁxed and permeabilized withClinical and Developmental Immunology 3
methanol and 0.1% Triton, respectively, and blocked with
4% BSA and 6% normal goat serum in PBS, washed, then
incubated with SOCS3 antibody at 100μg/mL (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) or rabbit IgG as
control, during 1 hour at room temperature. The slides were
washed again and thenexposed to Texas Redconjugated goat
antirabbit IgG (Santa Cruz Biotechnology, Inc.) overnight
at 4◦C. The slides were observed by confocal microscopy
(Leica Microsystems, Wetzlar, Germany). The ﬂuorescence
intensity over the area of a single cell was integrated, and
nonspeciﬁc ﬂuorescence (negative control) was subtracted.
Net ﬂuorescence intensity was divided by the average area of
theeosinophil inμm2 and expressed as ﬂuorescenceintensity
units(FIU)/μm2. Forstatistical analysis, averagenet intensity
values were calculated from a minimum of 100 cells per
sample.
2.6. Immunocytochemistry. Slides with puriﬁed eosinophils
were treated with methanol and 3% hydrogen peroxide in
PBS to block endogen peroxidase. Then, slides were blocked
with 4% BSA and 6% normal goat serum in PBS, washed,
and then exposed to SOCS3 antibody at 60μg/mL or rabbit
IgG as control for 30min at room temperature, and stained
with the LSAB and System HRP Kit, according to the
manufacturer’s instructions (DAKO, Carpinteria, CA, USA).
The slides were then lightly stained with hematoxylin and
examined.
2.7. Western Blot Analysis. The lysates from puriﬁed
eosinophils (10μg total protein), and 5μg recombinant
SOCS3 (rSOCS3) as positive control (Santa Cruz Biotech-
nology, Inc.), were resolved on SDS-PAGE and analyzed
by Western blotting, using a 1:200 dilution of SOCS3
antibody or rabbit IgG as isotype control. The secondary
antibody, HRP-conjugated goat antirabbit IgG (Santa Cruz
Biotechnology, Inc.), was diluted 1:1000.
Chemiluminescent protein bands were detected by an
ECL detection system (Amersham Biosciences, GE Health-
care, Buckinghamshire, UK) according to the manufacturer’s
protocol.Theproteinconcentrationwasestimated according
to the method of Bradford [25].
2.8. RNA Extraction and Real-Time Quantitative PCR
of SOCS3 and SOCS5. Total RNA was extracted from
eosinophils, CD4T cells, and bronchial biopsies according to
TRIzol reagent protocol (Invitrogen Life Technologies, CA,
USA).Bronchial biopsieswere homogenized previously.Two
micrograms of RNA were DNase treated, followed by reverse
transcription according to the kit instructions (Applied
Biosystems, Warrington, UK). TaqMan PCR was performed
using a 20μL ﬁnal reaction volume containing 10μlo f
TaqMan Universal PCR Master Mix (Applied Biosystems,
Branchburg, NJ, USA), 1μl of 20X Assays-on-Demand Gene
Expression Assay Mix, and 9μl of cDNA diluted in RNase-
free water. Each assay was performed in triplicate. The PCR
conditions used in all reactions were 2min at 50◦Ca n d
10min at 95◦C, with 40 two-step cycles (95◦Cf o r1 5 s
and 60◦C for 60s). Assays-on-Demand Gene Expression
primers speciﬁc for SOCS3, SOCS5, and rRNA (used
as an endogen) were obtained from Applied Biosystems
(http://www.appliedbiosystems.com/).Thegenesanalyzedin
this study were examined for their relative expression by
means of the ΔΔCT method [26].
2.9. Eosinophil Degranulation. To determine the release
of eosinophil peroxidase (EPO) from puriﬁed human
eosinophils, cells were resuspended in assay buﬀer (PBS,
0.1% BSA, 10nm HEPES, 10nm Glucose; pH: 7.4) at
1 × 106 cells/mL, mixed with cytochalasin B (10μg/mL),
and 50-μL aliquots were loaded into the wells of a 96-
well microplate. Cells were stimulated with 20μLo fC 5 a
(300nM) for 20min at 37◦C. Thereafter, 60μlo fH 2O2
(1mM) were added to each well to start the peroxidase
reaction. To detect the reaction, 70μlo f2 . 8 m Mt e t r a m -
ethylbenzidine was used. Following incubation for 1min
at room temperature, the peroxidase reaction and the
color development were stopped with 4M acetic acid [27].
Microplates were analyzed on a bench reader at a wavelength
of 630nm. Data were expressed as the percentage of the
maximal control response (C5a at 300nM).
2.10. Statistical Analysis. The subject characteristics were
described using descriptive statistics and expressed as geo-
metric mean and standard deviation (SD), and median and
range.
Results were compared and evaluated using the Kruskal
Wallis test and posttest Dun’s multiple comparison tests.
Correlation coeﬃcients and statistical signiﬁcance were
determined using Spearman correlation coeﬃcient. Statis-
tical signiﬁcance was recognized at P ≤ .05. Statistical
analyses were performed using GraphPad InStat3(GraphPad
Software Inc., San Diego, CA, USA).
3.Results
3.1. Clinical Characteristics of the Subjects. Eight subjects
with NAEB, six subjects with asthma, and nine healthy
control subjects were recruited from the Fundaci´ on Jimenez
D´ ıaz Allergy Clinic outpatients and staﬀ.T h es u b j e c t s ’
clinical characteristics are shown in Table 1.
The age of asthma and NAEB patients was very similar
(41.75 ± 8.94 and 38.55 ± 12.06 years, resp.), and no
diﬀerences existed in the evaluated parameters as a function
of age or gender in adult patients with asthma or NAEB.
Predicted values for FEV1 fell within a normal range,
although asthmatic patients showed a signiﬁcant decrease
compared to healthy control subjects and NAEB patients
(P<. 05). The median percentage of eosinophils on whole
blood was signiﬁcantly higher in the subjects with NAEB
and asthma than in healthy control subjects (4.4%, 2.66%,
and 0.14%, resp.; P<. 01 and P<. 05). In concordance
with these data, sputum eosinophils were also statistically
higher in NAEBand asthma patients than in healthy controls
(15.9%, 15.1%, and 2.1% resp.). No signiﬁcant diﬀerences
were observed in the eosinophil count between patients with
asthma and patients with NAEB, as shown in Table 1.T h e
IgE level in patients with NAEB and asthma was signiﬁcantly
higher than in healthy controls (P<. 05). There was4 Clinical and Developmental Immunology
Table 1: Clinical characteristics of study subjects.
Healthy controls Nonasthmaticeosinophilic bronchitis (NAEB) Asthma
N 986
Age (years) 23 (20–30) 40 (31–55) 37(21–61)
Male (%) 4 (44.4%) 4 (50%) 3 (50%)
Atopy (%) 0 5 (62.5%) 3 (50%)
FEV1 predicteda 105 (100–129) 108.95 (96–115)§ 99,47 (73–110)∗
FEV1/FVCa 85 (79–92) 80.6 (74.5–89.6) 78,91 (77.6–95.2)
Total IgE (kU/L)a 21.15 (4.52–144) 163 (34.50–605)∗ 65.2 (57.6–360)∗
Eosinophil count (%) 0.14 (0–3.32) 4.40 (1.5–8.39)† 2.66 (1.34–7.92)∗
Sputum eosinophils (%)a 2.1 (0.1–9.7) 15.9 (2–35) 15.1 (0.6–52.3)
PGE2 in sputum supernatant (pg/mL)a 2.89 (0.78–5.28) 15.582 (3.81–1336)∗ 33.8 (12.9–54.7)
FVC: forced vital capacity, FEV1: forced expiratory volume in the ﬁrst second.
aMedian (range).
∗P<. 05 (versus healthy control; Kruskal Wallis test; posttest Dunn’s multiple comparison test).
†P<. 01(versushealthy control; Kruskal Wallis test; post test Dunn’s multiple comparison test).
§P<. 05 (versus asthma patients; Kruskal Wallistest; post test Dunn’s multiplecomparison test).
a tendency toward higher levels of PGE2 in patients with
NAEB (P<. 05) and asthma (not signiﬁcant).
3.2. SOCS Gene Expression Correlates with Th2 Respira-
tory Disorders. Asthma and NAEB are allergic diseases
characterized by massive inﬁltration of eosinophils and T
cells secreting Th2 cytokines into the pathologic site. We
therefore examined whether puriﬁed CD4 T cells (>98%)
from patients with NAEB and asthma had higher levels of
SOCS3 gene expression as consequence of the preferential
developmentof Th2 cells. Expressions of SOCS3 and SOCS5
mRNA were analyzed by real-time quantitative PCR in
peripheral CD4 T cells from adult patients with NAEB,
asthma and healthy controls.
The expression of SOCS3 mRNA in patients with
asthma and NAEB was signiﬁcantly higher than in healthy
individuals(P<. 05andP<. 01,resp.; Figure 1(a));however,
no signiﬁcant diﬀerence was observed in the expression of
SOCS5 between patients and controls (Figure 1(b)).
3.3. Eosinophils from Donors with Th2 Respiratory Disor-
ders Exhibit Increased SOCS3 mRNA Expression in Com-
parison to Normal Eosinophils. Because the accumulation
o fe o s i n o p h i l si saf e a t u r eo fb o t ha s t h m aa n dN A E B ,
we determined if eosinophils are able to transcribe and
translate mRNA for SOCS3. Thus, SOCS mRNA expression
in puriﬁed eosinophils (>98%) from patients and healthy
individuals was studied. SOCS3 mRNA levels in patients
with NAEB were higher than in healthy controls (P<. 01,
Figure 1(c)); although there was a weak SOCS3levelincrease
inpatientswithasthma(1.51-fold),itdidnotreachstatistical
signiﬁcation versus healthy subjects. SOCS5 expression was
higher in eosinophils from patients, but there were no sig-
niﬁcant diﬀerences between the patient groups and control
subjects (Figure 1(d)). As elevation of serum IgE is a charac-
teristic of patients with NAEB and asthma, we determined
the correlation between serum IgE and the expression of
SOCS3. Individuals with a high expression of SOCS3 had
high levels of serum IgE (P<03, r: 0.5; data not shown).
3.4. Diﬀerential Expression of SOCS3 mRNA between Bron-
chial Biopsies from Asthmatics and NAEB Patients. The lung
undergoes dramatic changes in asthma and NAEB. Because
SOCS3 is involved in the regulation of the Th1/Th2 axis in
allergic diseases, we measured the SOCS3 mRNA expression
in bronchial biopsies from healthy controls, asthmatics, and
NAEB subjects (Figure 1(e)).
Our results showed that SOCS3 mRNA expression in
bronchialbiopsieswas strikinglyincreased (12.7-foldhigher)
in subjects with NAEB as compared with asthmatics (P<
.05).
3.5. Identiﬁcation of SOCS3 in Eosinophils by Immunocy-
tochemistry, Confocal Microscopy, and Immunoblotting. Im-
munocytochemistry,confocalmicroscopy,andimmunoblot-
ting were performed to conﬁrm the expression of SOCS3
in eosinophils. Figure 2 shows an example of highly
puriﬁed eosinophil preparations from asthmatics (Figures
2(b) and 2(f)), NAEB (Figures 2(c) and 2(g))a n dh e a l t h y
subjects (Figures2(d) and 2(h)), in which eosinophils clearly
show the characteristic bilobular nuclei of mature blood
eosinophils. There were eosinophils positively immunos-
tained for SOCS3 in asthmatics and NAEB samples, as
indicated by the expression of the brown reaction product
(Figures 2(b) and 2(c), resp.) or red ﬂuorescence (Figures
2(d) and 2(h), resp.). The expression of SOCS3 protein
measured as ﬂuorescence intensity was higher in patients
with NAEB (30.56 ± 8.81FIU/μm2;F i g u r e2(g))t h a ni n
asthmatics (12.35 ± 5.5FIU/μm2;F i g u r e2(f))w h e r e a si n
healthy controls was hardly intense (5.765 ± 2.64FIU/μm2
Figure 2(h)). Similar results were obtained by immunocyto-
chemistry (Figures 2(c) and 2(b)).
When we examined the distribution of SOCS3 in
eosinophils, using both techniques we showed that SOCS3
immunoreactivity or immunoﬂuorescence was largely con-
ﬁned to the eosinophil cytoplasmic compartment with
granular expression pattern (Figures 2(b), 2(c), 2(f),a n d
2(g)). The negative control was treated with HRPO isotype
antibody, and the absence of speciﬁc staining is revealedClinical and Developmental Immunology 5
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Figure 1:SemiquantitativeexpressionofSOCS3andSOCS5genes inperipheral blood puriﬁed CD4 Tcells andeosinophils.Relative mRNA
levelsofSOCS3andSOCS5inCD4Tcells((a)and(b)),andeosinophils((c)and(d))ofhealthycontrols,asthmaticandNAEBpatients were
determined by real-time quantitative PCR. Values were normalized with rRNA gene used as an endogen. Black boxes represent the healthy
control group (mean ± SD, n = 9), white boxes represent the asthmaticpatient group (mean ± SD, n = 6), and lineated boxes represent the
NAEB group (mean ± SD, n = 8). Signiﬁcant diﬀerences in the levels of SOCS3 expression in CD4 T cells were obtained for asthmatic and
NAEB patients versus the healthy control group (∗P<. 05 and ∗∗P<0.01, resp.). In eosinophils, the SOCS3 level was signiﬁcantly higher
in NAEB patients than in healthy controls (∗∗P<. 01). In the case of SOCS5, no signiﬁcant diﬀerences were found between the groups. (e)
SOCS3 mRNA levels in bronchial biopsies from healthy controls (mean ± SD, n = 2), asthmatics (mean ± SD, n = 2), and NAEB patients
(mean ± SD, n = 4). Signiﬁcantdiﬀerences in the levels of SOCS3 expression were obtained for asthmatic versus NAEB patients (∗P<. 05).
The results represent relative gene expression, as determined by the ΔΔCT method.6 Clinical and Developmental Immunology
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Figure 2: SOCS3 expression in peripheral blood eosinophils from Th2 patients analyzed by immunohistochemical, immunoﬂuorescence,
and Western blot techniques. Eosinophils from asthmatic and NAEB patients within healthy controls were adhered to slides and incubated
with peroxidase-conjugated goat antirabbit IgG against SOCS3 antibody ((b), (c), and (d)) or rabbit IgG as a control (a), and Texas Red
conjugated goat antirabbit IgG against SOCS3 antibody ((f), (g), and (h)) or rabbit IgG as a control (e). The slides were observed by optical
((a), (b), (c), (d)) or confocal ((e), (f), (g) and (h)) microscopy. Western blot analysis of the cytosolic extract of puriﬁed eosinophils was
achievedusingantibody againstSOCS3(i).Lane1:recombinantSOCS3wasloadedasapositivecontrol;lane2:eosinophillysatefromNAEB
patients; lane 3: eosinophil lysate from healthy control patients; lane 4: isotype negative control. The picture is a representative example of
5 individuals, all displaying similar results. (j): SOCS3 bands were quantiﬁed by densitometry and corrected by actin expression; data are
expressed as the mean ± SD, n = 5, ∗P<. 05 (2: NAEB; 3: healthy patients).
Figure 2(a).A l s o ,F i g u r e2(e) represents images taken from
Texas Red isotype control, and demonstrates that there was
negligible autoﬂuorescence or nonspeciﬁc binding in these
samples.
Finally, SOCS3 protein production by eosinophils was
veriﬁedbyWesternblot,usingSOCS3antibody(Figure2(i)).
The result pointed out a protein band with a similar molec-
ular weight to the commercial positive control (rSOCS3,
38kDa) in the protein lysates of highly puriﬁed eosinophils
from patients with NAEB and control subjects. The SOCS3
levels were quantiﬁed by densitometry and normalized
to actin levels (Figure 2(j)), and the data demonstrated
that the quantiﬁed band was statistically more intense in
eosinophils from patients compared to healthy individuals
(P<. 05). This data conﬁrm the SOCS3 protein expression
in eosinophils. Figure 2 shows a representative example of 5
individuals, all of whom display similar results.
3.6. Th2 but Not Th1 Cytokines Stimulate SOCS-3 mRNA Ex-
pression in Eosinophils. The increased expression of SOCS3
in eosinophils from patients with NAEB and asthma com-
pared with controls is probably due to factors that could
regulate SOCS3 expression in these cells under disease
conditions. For this reason, in vitro eﬀects of Th2 and Th1
cytokines in SOCS3 mRNA expression in eosinophils were
assessed using real-time quantitative PCR.Clinical and Developmental Immunology 7
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Figure3:SOCS3expression inperipheral bloodeosinophilstreated withTh2cytokinesandIFN-γ.Puriﬁedeosinophilsfromhealthydonors
were cultured with10ng/mLofIL-4 (a),IL-5 (b),IL-13 (c),or IFN-γ (d) fordiﬀerent periods oftime. Dose-response curves were performed
with IL-4, IL-5, IL-13, or IFN-γ (e)–(h) at maximal time response; SOCS3 mRNA was measured by real-time quantitative PCR. The results
are expressed as a fold induction relative to untreated eosinophils, and signiﬁcant diﬀerences are indicated. Data represent the geometric
mean ± SD from four individuals, and each measure was performed in triplicate.
The treatment of eosinophils from healthy subjects with
recombinant human IL-4, IL-5, or IL-13 (Th2 cytokines)
induces upregulation of SOCS3 mRNA expression in a time-
dependent manner, with higher levels of SOCS3 mRNA at
120min for IL-4 (Figure 3(a)) and at 60min for IL-5, and
IL-13 (Figures 3(b) and 3(c)). Furthermore, SOCS3 mRNA
expression was signiﬁcantly enhanced by the incubation
with human recombinant IL-4, IL-5, or IL-13 in a dose-
dependent manner (Figures 3(e), 3(f),a n d3(g)). Our results
showed that SOCS3 production was strikingly increased
(14.10-fold; Figure 3(f)) in IL-5-induced eosinophils as
compared with IL-4-, or IL-13-induced eosinophils (3.71-
fold; Figure 3(e) and 3.39-fold; Figure 3(g),r e s p . ) .I nc o n -
trast, when eosinophils were cultured with IFN-γ, typically
secreted by Th1 cells, SOCS3 expression was not statistically
aﬀected at any dose or time assayed (Figures 3(d) and
3(h)). Similar results came out when stimulation was carried
out with IL-2, another well-known Th1 cytokine (data not
shown). Collectively, these results demonstrate that SOCS3
expression is activated in response to increased amounts of
Th2 cytokines.
We wanted to compare the eﬀects of Th2 cytokines on
the expression of SOCS3 mRNA in eosinophils from healthy
controls, asthmatics, and NAEB patients. When eosinophils
from asthmatics and NAEB patients were treated during
optimal period of time with IL-4, the relative level of SOCS3
mRNA expression was signiﬁcantly lower than in healthy
controls with the same treatment (0.8 ± 0.3, 0.6 ± 0.6, and
3.71 ± 1.2r e s p . ,P<. 05, Figure 4). Similar results were
obtained when eosinophils were cultured with IL-5 (3.02 ±
2.2, 1.86 ± 0.6a n d1 4 .11 ± 4.2, resp., P<. 05, Figure 4).
However,stimulationwithIL-13didnotsigniﬁcantly modify
SOCS3 mRNA expression.
3.7. PGE2 Treatment Produces Increased SOCS3 mRNA Ex-
pression in Eosinophil Cultures. Because it has been reported
that PGE2 upregulates SOCS3 gene expression in diﬀerent
cell types, we examined the eﬀect of PGE2 on SOCS3
expression in eosinophils from healthy subjects. We tested
diﬀerent doses of PGE2 (10−4 and 10−6 M), and SOCS3 gene
activation was determined by real-time quantitative PCR.
After treatment of eosinophils with PGE2,S O C S 3m R N A8 Clinical and Developmental Immunology
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Figure 4: SOCS3 mRNA expression in Th2-stimulated eosinophils
from healthy controls, asthmatics, and NAEB patients. Eosinophils
fromhealthycontrols,asthmatics,andNAEB patientswerecultured
with 10ng/mL of IL-4 or IL-5, or IL-13 during 60min. SOCS3
mRNA wasmeasured by real-time quantitative PCR. The results are
expressed as a fold induction relative to untreated eosinophils, and
signiﬁcant diﬀerences are indicated. Data represent the geometric
mean ± SD from three individuals, and each measure was
performed in triplicate.
expression was upregulated at 60 and 120min (Figure 5(a)).
This regulation was dose dependent, and signiﬁcant diﬀer-
ences were found compared with the control eosinophils
(Figure 5(b)). PGE2,10−4 Ma n d1 0 −6 M, increased SOCS3
gene expression by 7.76- and 5.58-fold, respectively.
These data indicate that PGE2 induces SOCS3 mRNA
expression,suggestingthatPGE2 canbearegulatorymetabo-
lite of SOCS3 protein production in eosinophils.
3.8. Th2 Cytokines and PGE2 Inhibit Eosinophil Degranu-
lation. We assessed the biological signiﬁcance of SOCS3
augmentation in eosinophils by examining the eﬀects of
Th2 cytokines and PGE2 in eosinophil degranulation. We
observed that C5a-induced release of EPO was signiﬁcantly
attenuated by both Th2 cytokines and PGE2 (Figure 6).
All inhibitions obtained were statistically signiﬁcant and is
ranged between 32.5% and 77%, obtained with PGE2 and
IL-5, respectively.
4.Discussion
Our results reveal that eosinophils are able to transcribe and
express SOCS3 at the protein level, and this production is
upregulated by IL-4, IL-5, IL-13, and PGE2. In addition,
SOCS3 production was increased in patients with NAEB.
These data suggest that eosinophils can contribute to the
regulation of the inﬂammatory response through SOCS3
production.
This study examined SOCS protein expression in blood
eosinophils from patients with two Th2 conditions (asthma
and NAEB). These respiratory disorders are characterized by
the recruitment and activation of inﬂammatory cells, includ-
ing eosinophils and lymphocytes, which produce cytokines
[22]. However, the amplitude and duration of the response
depend on precise ﬁne-tuning and coordination of immune
cell responses, and theseaspects are regulated by endogenous
feedback regulators of cytokine activities. Prominent among
this class of intracellular regulators are members of the
SOCS proteins family [5, 7]. Signiﬁcant interest in the
SOCS family stems from the belief that SOCS proteins
may integrate multiple cytokine signals and mediate cross-
communication between antagonistic cytokines elaborated
by diﬀerent cells through inhibitory eﬀects on cytokine
receptors and signaling molecules.
SOCS proteins exert negative regulation of cytokine
signaling in a variety of ways and are known to be involved
in the pathogenesis of many inﬂammatory diseases. Hence,
some members of the SOCS protein family, and SOCS1,
SOCS3, and SOCS5 in particular, participate in regulation
of the Th1/Th2 balance [28, 29].
According to this, the evaluation of SOCS3 in bronchial
biopsies from healthy controls, asthmatics, and NAEB
subjects ascertained the expression at mRNA level of this
negative regulator. Notably, this expression was enhanced in
bronchial biopsies from NAEB subjects in comparison with
those from healthy control or asthmatics.
Considering that eosinophils play a prominent pro-
inﬂammatory role in allergic airway inﬂammation, and
noting that other authors have recently described the SOCS3
expression in diﬀerent cellular types, such as macrophages
and microglia [30], we determined if blood eosinophils are
able to express SOCS3 and SOCS5 at the protein level and
thus contribute to regulate cytokine balance in NAEB and
asthma, conditions in which eosinophils are one of the most
important cell types.
We have demonstrated that blood eosinophils express
SOCS proteins. SOCS3 and SOCS5 gene expressions were
detected by real-time quantitative PCR, and SOCS3 pro-
tein was detected in the cytosol of blood eosinophils
with granular expression pattern by immunohistochemistry,
immunoﬂuorescence, and immunoblotting.
Moreover, blood eosinophils from patients with Th2
disorders exhibit higher levels of SOCS3mRNA than healthy
subjects. These data suggest that eosinophils may play an
important role in regulating inﬂammation in respiratory
disorders through SOCS3 expression. We tested the eﬀects
of Th2 cytokines (IL-4, IL-5, and IL-13) on the expression
of SOCS3 in blood eosinophils in vitro,a n dw es h o w e d
upregulation of SOCS3 expression in a time- and dose-
dependentmanner, thuscorroborating SOCS-3activation in
response to the Th2 environment under disease conditions.
We also found that SOCS-3 expression in blood eosinophils
from patients with asthma and NAEB was correlated with
serum IgE levels (r = 0.5, P<. 03). This result canClinical and Developmental Immunology 9
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Figure 5: PGE2 stimulation of SOCS3 mRNA expression. Puriﬁed eosinophils from healthy donors were cultured with 10−4 Mo fP G E 2
for up to 120min (a), and with increasing doses of PGE2at 120min (b), and SOCS3 mRNA was measured by real-time quantitative PCR.
The results are expressed as a fold induction relative to untreated eosinophils, and signiﬁcant diﬀerences are indicated. Data represent the
geometric mean ± SD from four individuals, and each measure was performed in triplicate.
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Figure 6: Th2 cytokines and PGE2 inhibit eosinophil degranu-
lation. Puriﬁed human eosinophils were pretreated with vehicle,
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be since both phenomenons are occurring simultaneously
after IL-4 stimulation. The increase of SOCS3 expression in
response to Th2 cytokines in healthy individuals is markedly
greater than in those from asthmatic and NAEB patients,
indicating that eosinophils from individuals with asthma
and NAEB had impaired upregulation of SOCS3 after Th2
stimulation. These results may be explained because, inthese
patients, Th2 cytokinesare present in the microenvironment
conferring an intrinsic Th2 status that could provide a neg-
ative feedback mechanism, so further stimulation hardly
causes additional eﬀect in SOCS3 mRNA expression. Similar
ﬁndings have been published [31, 32].
It was also interesting to evaluate the potential role
of IFN-γ in regulating SOCS3 expression in puriﬁed
eosinophils due to its ability to counteract the eﬀects of Th2
cytokines in various cells types, including T cells, B cells,
endothelium, and epithelium [33]. Nevertheless, our results
did not reveal any variation in the SOCS3mRNAexpression,
suggesting that SOCS3 is not regulated by this mediator.
We also analyzed the expression of SOCS3 and SOCS5
in peripheral blood CD4 T cells from patients with NAEB
and asthmatics compared with healthy controls. The results
showed that the expression of SOCS3 in patients was
signiﬁcantly higher than in control subjects, and we found
a correlation between level of SOCS3 mRNA in CD4+ cells
and IgE level (r = 0.58, P<. 04). Similarly, Seki et al. [32]
reported that the level of SOCS3 mRNA in peripheral CD3+
cells was elevated and correlated with the serum IgE level
in patients with atopic dermatitis and asthma. Analysis of
the levels of SOCS5 gene expression indicated that there was
no signiﬁcant change between the groups. These results are
in concordance with other studies in which there were no
diﬀerences in SOCS5 gene expression level between healthy
subjects and those with asthma or atopic dermatitis [34, 35].
SOCS3 has the potential to modify responsiveness of
airways to important cytokines. SOCS3 is expressed in
eosinophils, and although cytokines themselves are likely
to contribute to this, we have shown that PGE2,w h i c hi s
produced in airways, can also stimulate SOCS3 expression
in eosinophils. Several studies have reported that PGE2
treatment not only stimulates the expression of SOCS3 in
diﬀerent cells, but also prolongs the stability of SOCS3
mRNA [19–21, 36]. Recently, we have described increased
PGE2 levels in the airways of patients with NAEB [16], so10 Clinical and Developmental Immunology
it is not surprising that individuals with NAEB who have
highPGE2 levelsalso havehighlevelsofexpression ofSOCS3
(r = 0.81, P<. 05). When we analyzed the eﬀect of PGE2 in
SOCS3 expression in blood eosinophils in vitro,w eo b s e r v e d
a signiﬁcant increase in SOCS3 mRNA expression in a time-
and dose-dependent manner.
The diﬀerential regulation of SOCS3 expression by
distinct stimuli creates a situation whereby potentiation of
SOCS3 expression is possible. In our study, we observed that
IL-4, IL-5, and IL-13, at doses to produce maximal SOCS3
expression, inhibited eosinophil degranulation, probably
through SOCS3 augmentation. According with these results,
Hebenstreit et al. show that SOCS1 and SOCS3 can nega-
tively regulate IL-4- and IL-13-induced CCL26 expression
[37], which is one of the main attractants of eosinophils.
Both results highlight an important mechanism SOCS3
mediated for regulating the activation and recruitment of
eosinophils during inﬂammation by limiting the eﬀects of
Th2 cytokines.
Also, in our study eosinophils degranulation is par-
tially inhibited by PGE2. Perhaps, in addition to other
eﬀects, PGE2-induced SOCS3 expression may be impor-
tant in regulating responsiveness to cytokines and could
be involved in the pathogenesis and regulation of Th2
respiratory disorders. Recently, Sturm et al. point out that
prostaglandin E2 inhibits eosinophil traﬃcking through
EP2 receptors [38]. This data provide a novel mechanistic
concept to substantiate previous observations that PGE2
acts as an anti-inﬂammatory mediator in human airways
[15–18].
The diverse and speciﬁc eﬀects of PGE2 depend on
diﬀerent EP receptor subtypes. In eosinophils, all forms of
EPreceptor genesare expressed [39];inourpatients,EP2 and
EP4 wereexpressedatahigherlevelwhen comparedwithEP1
and EP3(data not shown),so these results suggest that PGE2-
inducedmodulation of cytokinessignaling can occurvia EP2
and/or EP4 receptors, although further studies are necessary
to conﬁrm this notion.
5.Conclusions
The most important ﬁnding in the current study was that
expression of SOCS3 protein has been described for the
ﬁrst time in eosinophils, and as SOCS3 has an important
role in regulating the onset and maintenance of Th2-
mediated allergic immune diseases, this could contribute to
improve the understanding of the pathways implicated in
the regulation of these diseases. It is also a novel ﬁnding
thatPGE2,whichis highlyproducedinsomeTh2diseases,can
modulate eﬀects on the immune response via regulation of
cytokine signaling.
A precise regulation of both, the magnitude and dura-
tion of cytokine signaling, is essential for orchestration of
immune reactions. Interventions that regulate Th2 cytokine
eﬀector pathways are attractive as potential therapeutic
targets. The implication of SOCS proteins in the regulation
o ft h eT h 1 / T h 2b a l a n c es u g g e s t sar a n g eo fn e wt h e r a p e u t i c
strategies that might reduce Th2-induced inﬂammation and
its consequences in eosinophilia.
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